Terms: = Prostate cancer AND NT5C2, ENSG00000076685, 22978, P49902, PNT5, NT5B, GMP, cN-II AND Treatment
9 results:
1. A novel direction modulated brachytherapy technique for urethra sparing in high-dose-rate brachytherapy of prostate cancer.
Meftahi M; Qiu RLJ; Patel P; Song WY; Yang X
Radiother Oncol; 2023 Sep; 186():109801. PubMed ID: 37423478
[TBL] [Abstract] [Full Text] [Related]
2. The cGAS-STING pathway-related gene signature can predict patient prognosis and immunotherapy responses in prostate adenocarcinoma.
Zhuo X; Dai H; Yu S
Medicine (Baltimore); 2022 Dec; 101(50):e31290. PubMed ID: 36550819
[TBL] [Abstract] [Full Text] [Related]
3. A Brief Review of Radioactive Materials for Therapeutic and Diagnostic Purposes.
Bharti M; Alam MA; Rao GSNK; Sharma PK
Curr Radiopharm; 2023; 16(1):23-37. PubMed ID: 36306460
[TBL] [Abstract] [Full Text] [Related]
4. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract] [Full Text] [Related]
5. Pharmaceutical good manufacturing practice: Leuplin
Wada M; Ozaki A; Miyachi T; Tanimoto T; Crump A
Invest New Drugs; 2021 Aug; 39(4):1167-1169. PubMed ID: 33559805
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract] [Full Text] [Related]
7. Bench to bedside development of gmp grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
ter Heine R; Lange R; Breukels OB; Bloemendal HJ; Rummenie RG; Wakker AM; de Graaf H; Beekman FJ; van der Westerlaken MM; Malingré MM; Wielders JP; van den Berg L; Hendrikse NH; de Klerk JM
Int J Pharm; 2014 Apr; 465(1-2):317-24. PubMed ID: 24560635
[TBL] [Abstract] [Full Text] [Related]
8. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract] [Full Text] [Related]
9. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
[TBL] [Abstract] [Full Text] [Related]
